Rising Prevalence Of Chronic Myeloid Leukemia (CML) Fuels Growth Of Dasatinib Drugs Market Driver: A Major Catalyst in the Evolution of the Dasatinib Drugs Market in 2025

What industry-specific factors are fueling the growth of the dasatinib drugs market?
The growing incidence of chronic myeloid leukemia (CML) is anticipated to drive the expansion of the dasatinib drug market in the future. Chronic myeloid leukemia (CML) is a form of cancer that affects both the bone marrow and blood, characterized by the abnormal growth of white blood cells. The rising incidence of CML is primarily influenced by factors such as lifestyle choices, unhealthy eating habits, and escalating environmental risks. Dasatinib drugs are effective in treating CML by targeting BCR-ABL (gene fusion), a tyrosine kinase protein produced due to the Philadelphia chromosome mutation, which accelerates the uncontrolled growth of malignant white blood cells. For example, in January 2023, the American Cancer Society (ACS), a U.S.-based health organization, reported a rise in CML cases to 8,930, up from 8,860 in 2022 in the U.S. Thus, the growing prevalence of CML is fueling the demand for dasatinib drugs.

Get Your Dasatinib Drugs Market Report Here:
https://www.thebusinessresearchcompany.com/report/dasatinib-drugs-global-market-report

What Is the projected market size and growth rate for the dasatinib drugs market?
The dasatinib drugs market has expanded significantly, expected to grow from $1.45 billion in 2024 to $1.55 billion in 2025 at a CAGR of 6.9%. Market expansion is driven by the increasing prevalence of chronic myeloid leukemia (CML), growth in targeted cancer therapies, advancements in tyrosine kinase inhibitor (TKI) research, increased investment in oncology research, and rising clinical trials.

The dasatinib drugs market size is expected to expand significantly, reaching $2 billion by 2029 at a CAGR of 6.6%. Growth will be supported by increased investment in oncology drug pipelines, the rising prevalence of drug-resistant leukemia cases, the growing availability of generic dasatinib drugs, efforts to minimize chemotherapy side effects, and greater awareness and early diagnosis of leukemia. Major trends expected in this period include the adoption of personalized medicine, the implementation of companion diagnostics, the development of new formulations, advancements in combination therapies, and the rise of biosimilars.

Get Your Free Sample Now - Explore Exclusive Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=19023&type=smp

What new trends are reshaping the dasatinib drugs market and its opportunities?
In the dasatinib drugs market, companies are focusing on generic drugs to increase market accessibility and provide affordable treatment options. In September 2024, Apotex Corp. launched the first generic version of Sprycel (dasatinib) in the United States, making it more accessible for patients and increasing competition in the leukemia treatment market.

What major market segments define the scope and growth of the dasatinib drugs market?
The dasatinib drugsmarket covered in this report is segmented -

1) By Product Type: Tablets, Oral Suspension, Other Products
2) By Indication: Chronic Myeloid Leukemia, Acute Lymphoblastic Leukemia, Other Indications
3) By End User: Hospitals, Specialty Clinics, Home Healthcare

Subsegments:
1) By Tablets: 20 mg Tablets, 50 mg Tablets, 70 mg Tablets, 80 mg Tablets
2) By Oral Suspension: 20 mg Or 5 mL Oral Suspension, 40 mg Or 5 mL Oral Suspension
3) By Other Products: Injectable Formulations, Combination Therapies, Generic Dasatinib Products

Unlock Exclusive Market Insights - Purchase Your Research Report Now!
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=19023

Which region dominates the dasatinib drugs market?
North America was the largest region in the dasatinib drugs market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the dasatinib drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Which key market leaders are driving the dasatinib drugs industry growth?
Major companies operating in the dasatinib drugs market are Bristol-Myers Squibb Company, AstraZeneca plc, Novartis AG, Gilead Sciences Inc., Amgen Inc., Teva Pharmaceutical Industries Ltd., Otsuka Pharmaceutical Co. Ltd., Sandoz Group AG, Hetero Drugs Limited, Sun Pharmaceutical Industries Limited, MSN Laboratories Pvt. Ltd., Aurobindo Pharma Limited, Dr. Reddy's Laboratories Limited, Intas Pharmaceuticals Ltd., Cipla Limited, Hikma Pharmaceuticals plc, Lupin Limited, Zhejiang Hisun Pharmaceutical Co. Ltd., Biocon Limited, Alkem Laboratories Limited, Glenmark Pharmaceuticals Limited, Torrent Pharmaceuticals Limited, Alembic Pharmaceuticals Limited, Mylan N.V., Manus Aktteva Biopharma LLP

Customize Your Report - Get Tailored Market Insights!
https://www.thebusinessresearchcompany.com/sample.aspx?id=19023&type=smp

What Is Covered In The Dasatinib Drugs Global Market Report?

•Market Size Forecast: Examine the dasatinib drugs market size across key regions, countries, product categories, and applications.
•Segmentation Insights: Identify and classify subsegments within the dasatinib drugs market for a structured understanding.
•Key Players Overview: Analyze major players in the dasatinib drugs market, including their market value, share, and competitive positioning.
•Growth Trends Exploration: Assess individual growth patterns and future opportunities in the dasatinib drugs market.
•Segment Contributions: Evaluate how different segments drive overall growth in the dasatinib drugs market.
•Growth Factors: Highlight key drivers and opportunities influencing the expansion of the dasatinib drugs market.
•Industry Challenges: Identify potential risks and obstacles affecting the dasatinib drugs market.
•Competitive Landscape: Review strategic developments in the dasatinib drugs market, including expansions, agreements, and new product launches.

Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.

Contact Us
Europe: +44 207 1930 708,
Asia: +91 88972 63534,
Americas: +1 315 623 0293 or
Email: mailto:info@tbrc.info

Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.